Ambamustine in the second-line treatment of patients with small-cell lung cancer: A phase II fonicap study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 1, 2000, Pages 22-25

  Ardizzoni, Andrea ^a   Antonelli, G ^b   Ricci, S ^b   Frasci, G ^b   Rinaldi, M ^b   Boni, L ^b   Galletti, P ^b   Pennucci, M C ^b   Antonuzzo, A ^b   Gravina, A ^b   Galli, L ^b   Comella, G ^b   Conte, P F ^b   Salvati, F ^b   Rosso, R ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

Ambamustine; Second line chemotherapy; Small cell lung cancer

Indexed keywords

ALKYLATING AGENT; AMBAMUSTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; SURVIVAL ANALYSIS;

EID: 0034122631     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200002000-00005     Document Type: Article

References (16)

1. Hansen HH. Management of small-cell lung cancer. Lancet 1992; 339:846-9.
2. Grant SC, Gralla RJ, Kriss MG, et al. Single agent chemotherapy trials in small cell lung cancer, 1970-1990: the case for studies in previously treated patients. J Clin Oncol 1992;10:484-98.
3. Giaccone G. Second line chemotherapy in small cell lung cancer. Lung Cancer 1989;5:207-13.
4. Aisner J. Strategies for new drug identification in small cell lung cancer. Lung Cancer 1993;9(suppl 1):S99-107.
5. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969;46:516-25.
6. Yagi MJ, Zaniani M, Holland JF, et al. Increased cancericidal activity of PTT-119, a new synthetic bis-(2-chloroethyl) amino-1-phenylalanine derivative with carrier aminoacid II. In vivo bioassay. Cancer Chemother Pharmacol 1984;12:77-82.
7. Martoni A, Mazzei T, Mini E, et al. Phase I trial of a novel alkylating agent. Cancer Chemother Pharmacol 1986;18(suppl 1):192.
8. Tura S, Mazza P, Gherlinzoni F, et al. Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. Cancer Chemother Pharmacol 1989;23:123-5.
9. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1990;47:207-14.
10. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
11. Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996;14:2785-90.
12. Cormier Y, Eisenhauer EA, Muldal A. et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 1994;5:283-5.
13. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-9.
14. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group Study. J Clin Oncol 1995;13:1430-5.
15. Ardizzoni A, Hansen H, Dombernowsky P, et al. for the EORTC ECSG and LCCG. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer (SCLC): a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15:2090-6.
16. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 1994;30A:1058-60.